Objective: The article examines the objective, findings, and clinical context described in FDA expands talazoparib use in prostate cancer. Approach: Approval: T
The FDA approved talazoparib plus enzalutamide for adults with HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.
Eligible patients must have an HRR gene mutation identified by an FDA-authorized test; FoundationOneCDx and FoundationOne Liquid CDx are approved companion diagnostics.
In the 599-patient TALAPRO-3 trial, the combination reduced the risk of radiographic progression or death by 52% versus placebo plus enzalutamide (hazard ratio, 0.48).
Median radiographic progression-free survival was not reached with talazoparib plus enzalutamide and was 45.8 months with placebo plus enzalutamide; overall survival data were immature.
Grade 3 or higher anemia occurred in 51% of combination-treated patients versus 3% of controls, and blood counts should be monitored before treatment and monthly thereafter.
Objective: To develop and evaluate a compact, low-cost near-infrared spectrometer for identifying materials and measuring concentrations, and to explore its pot
ConvSpec is a near-infrared spectrometer measuring 4.8 × 6.2 × 0.6 cm, weighing 16.5 g, and costing an estimated $10 in components.
The device covers wavelengths from about 1,200 to 1,700 nm and collects and processes each spectrum in less than 0.4 seconds.
In internal tests, machine learning models correctly classified samples of plastics, pharmaceuticals, coffee, flour, and tea.
In solution experiments, ConvSpec measured ethanol, lactate, glucose, and ethylene glycol concentrations from 0.1% to 40%, with mean absolute errors of 0.006% to 0.017%.
Exploratory wrist-probe testing found that glucose models could not reliably predict levels in new participants, and the study did not establish ConvSpec as a clinical diagnostic test.
Objective: The article examines the objective, findings, and clinical context described in FDA expands weekly insulin use to children. Approach: Approval: The F
The FDA approved once-weekly insulin icodec-abae (Awiqli) for children aged 10 years and older with type 2 diabetes as an adjunct to diet and exercise.
The long-acting basal insulin is administered subcutaneously with a prefilled pen and reduces basal insulin injections from daily to weekly.
Pediatric approval relied on adult phase 3 ONWARDS findings and a single-dose pharmacokinetic study of 18 patients aged 10 to younger than 18 years.
The FDA expects similar glucose-lowering effects in pediatric and adult patients based on pharmacometric modeling, although no randomized efficacy trial was conducted in children.
Common adverse reactions include hypoglycemia, hypersensitivity, injection-site reactions, lipodystrophy, pruritus, rash, edema, and weight gain; clinicians should ensure correct weekly dosing.
Objective: To describe the 36-month clinical course of a patient with severe bilateral ocular injury from sodium amide. Approach: Case: Investigators followed a
A 23-year-old man sustained severe bilateral ocular injury when a sodium amide container exploded, causing extensive limbal ischemia and corneal opacification.
Corneal epithelial healing was prolonged, taking 2 months in the left eye and an estimated 90 to 143 days in the right eye.
Fibrovascular pannus invaded both corneas by 2.75 months and recurred or progressed despite anti-inflammatory treatment and repeated surgical resections.
At 36 months, refraction improved left-eye vision to 20/25, whereas right-eye uncorrected acuity ranged from 20/100 to 20/300 during months 30 to 36.
The single-patient report cannot establish typical outcomes or treatment effects, and healing remained ongoing at 3 years.
Objective: To describe a case of rapidly progressive primary cutaneous cryptococcosis with extensive tissue destruction despite no clinically apparent systemic
An 81-year-old man with transfusion-dependent myelodysplastic syndrome developed rapidly progressive right middle-finger cellulitis after a splinter injury.
Cryptococcus neoformans was identified in fungal cultures, and histopathology showed encapsulated yeast with narrow-based budding.
Despite empiric antibiotics and urgent exploration, extensive necrosis and digital arterial thrombosis led to amputation through the proximal interphalangeal joint.
Negative blood cultures and serum cryptococcal antigen tests, along with no systemic symptoms, supported localized infection, although occult dissemination was not definitively excluded.
After surgery and 9 weeks of antifungal therapy, the wound healed, and the patient remained well 6 months after treatment.
In a 24-week, multicenter, open-label trial, 506 adults recently hospitalized for heart failure were randomly assigned to mobile health management or usual care.
Mobile health management combined daily transmission of biometric data and symptom questionnaires with health care team review, alerts, and video consultations.
The primary endpoint of cardiovascular mortality or worsening heart failure occurred in 17% of the mobile health group and 41% of the usual care group.
Worsening heart failure occurred in 14% of patients receiving mobile health management and 39% receiving usual care; cardiovascular mortality occurred in 4% and 8%, respectively.
The authors noted limitations including the open-label design, lack of systematic adverse-event data, and uncertainty about staffing and workflow requirements for broader implementation.
A study of 327 public facilities across seven states and Delhi found the largest gaps in essential TB diagnostic access at the primary-care level.
Although national policy recommends AFB smear microscopy and chest X-ray at PHCs, complete availability of both generally ranged from 0% to 10% across surveyed regions.
Across tiers where tests are recommended, AFB microscopy was available in about 78% of facilities, CBNAAT and chest X-ray in about 51%, and fluorescence microscopy in 31% of district hospitals.
India had 97 CDST laboratories compared with an estimated need of 283, a shortfall of 62% based on the recommended ratio to TB treatment units.
The article calls for connected diagnostic networks, including expanded molecular testing, accessible chest radiography, specimen transport, and stronger culture and drug-susceptibility testing capaci
Objective: Investigate the genetic basis and molecular effects of Marfan syndrome in two affected domestic cats. Approach: Clinical assessment: Researchers desc
Two male littermate cats, Gary and Shaggy, had displaced eye lenses, unusually long limbs, and severe aortic enlargement consistent with Marfan syndrome.
Whole-genome sequencing identified the same rare FBN1 variant in both cats, which was absent from genomic data for more than 1,000 other cats.
Both cats inherited two copies of the variant, but long-read RNA sequencing showed that it did not completely disable FBN1.
Approximately 73% of the affected cat’s FBN1 transcripts lacked exon 22, while the remaining transcripts retained it and may allow some normal fibrillin-1 production.
The authors noted that the study involved only two related cats and did not directly analyze fibrillin-1 protein production.
Objective: Assess Trypanosoma cruzi infection and genetic diversity in common vampire bats in northern Belize, and explore possible overlap with parasite lineag
Among 207 vampire bats sampled at 2 sites in northern Belize, 86 (42%) tested positive for Trypanosoma cruzi.
Sequencing of 10 positive samples identified 5 T cruzi lineages, including TcBat and TcVI, which had not previously been documented in Belize.
A TcIV haplotype from a bat clustered with sequences from Belizean triatomine vectors and a 2020 human infection, suggesting a potential epidemiological connection but not proving direct transmission.
Adjusted infection odds were higher at Lamanai than at Ka’Kabish and higher in 2022 than in 2019; age, sex, and reproductive status were not associated with infection.
Limited sampling and sequencing prevented the study from establishing transmission pathways or estimating lineage frequencies across the broader bat population.
The review argues that proteostatic fitness should be considered a critical quality attribute for stem cell and extracellular vesicle products.
Conventional release tests do not routinely assess misfolded or oxidized proteins that may accumulate during cell manufacturing.
Repeated ex vivo expansion can impair protein-clearance processes, while senescent cells may release inflammatory molecules and extracellular vesicles reflecting their condition.
In neural stem cell models, extracellular vesicles containing oxidized SOD1 were associated with mitochondrial dysfunction and secondary senescence in recipient cells.
The authors propose senescence screening, EV cargo profiling, and targeted release assays, but note that thresholds require harmonization and cargo sanitization needs further assessment.
Objective: Develop and evaluate a tumor-targeted, nonviral platform for generating CAR-expressing immune cells within solid tumors. Approach: Delivery system: R
Researchers developed R8L-NI@Lipo, a tumor-targeted lipoplex designed to generate CAR-expressing T cells and NK cells within solid tumors.
The lipoplex delivers plasmid DNA encoding an NKG2D-based CAR and IL-15, with hypoxia-responsive elements designed to limit CAR expression to low-oxygen tumor environments.
In mouse models, the targeted lipoplexes accumulated in tumors and penetrated beyond tumor blood vessels, while CAR expression was higher under hypoxic conditions.
In the 4T1 model, treatment increased CD8+ T-cell infiltration 3.33-fold versus untreated controls, reduced mean tumor weight to about 9.2% of control, and produced complete regression in 2 of 6 mice.
Median survival increased from 22.5 to 42.5 days in the 4T1 model and from 22.5 to 44.5 days in the EMT6 model; safety findings suggested reduced off-target effects with hypoxia-responsive regulation.
Investors and partners increasingly seek clear clinical differentiation, credible execution, and a realistic path from science to patients and commercial viability.
Experts warn that underinvestment in early translational research could weaken the pipeline of companies and programs.
Manufacturing strategy, scalability, and cost control should be addressed early because they affect commercialization and patient access.
Companies are pursuing partnerships, licensing, mergers and acquisitions, and other financing approaches to support survival and further validation.
Experts emphasize focused programs that address unmet clinical needs, demonstrate efficacy, and offer practical delivery and real-world value.
Objective: The article examines the objective, findings, and clinical context described in Coronary Hypoxemia During VA-ECMO: Why Peripheral Oxygenation Monitor
Objective: Report a correction to the published article’s author name. Approach: Correction: The article initially misspelled Valsamo Anagnostou’s surname as “A
Objective: To correct an error in the data shown in the “White” section of Fig. 1d. Approach: Correction: The affected data were corrected in the HTML and PDF v
A correction to the article “Phenomic profiles and disease patterns in 1.9 million Our Future Health participants” was published online on September 10, 2026.
The correction was published in Nature Medicine.
The correction is available at https://doi.org/10.1038/s41591-026-04602-4.
Data in the “White” section of Fig. 1d were incorrect in the article’s initial version.
The data in the “White” section of Fig. 1d have been corrected in both the HTML and PDF versions.
Objective: The article examines the objective, findings, and clinical context described in Digital Health Engagement and Psychological Distress: Understanding T
Objective: The article examines the objective, findings, and clinical context described in More Than 250 Hospitals Pledge to Improve the Nutritional Quality of